Lineage Cell Therapeutics

Lineage Cell Therapeutics EBIT per Employee

The EBIT per Employee of Lineage Cell Therapeutics (LCTX) as of Oct 31, 2026 is -282,844.16 USD. In the previous year, EBIT per Employee was -278,935.06 USD — a change of 1.40% (lower).

EBIT per Employee

-282,844.16USD

YoY

1.40%

Last updated:

EBIT per Employee of Lineage Cell Therapeutics is 2025 -282,844.16 USD. EBIT per Employee of Lineage Cell Therapeutics was 2024 -278,935.06 USD. It decreases by 1.40% lower compared to the previous year.

The Lineage Cell Therapeutics EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-542,792.21 USD
Jan 1, 2019
-504,883.12 USD
Jan 1, 2020
-343,467.53 USD
Jan 1, 2021
-639,103.90 USD
Jan 1, 2022
-292,467.53 USD
Jan 1, 2023
-321,207.79 USD
Jan 1, 2024
-278,935.06 USD
Jan 1, 2025
-282,844.16 USD
The Lineage Cell Therapeutics EBIT per Employee history
YEAREBIT per EmployeeYoY
-282,844.16USD+1.40%
-278,935.06USD-13.16%
-321,207.79USD+9.83%
-292,467.53USD-54.24%
-639,103.90USD+86.07%
-343,467.53USD-31.97%
-504,883.12USD-6.98%
-542,792.21USD+7.44%
-505,220.78USD-34.03%
-765,805.19USD-10.40%
-854,662.34USD+29.85%
-658,215.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lineage Cell Therapeutics Stock analysis

What does Lineage Cell Therapeutics do? Lineage Cell Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of cell therapies for various diseases. Originally established in 1990 as VisiGenics Inc., specializing in proteomic and genetic analysis, the company later changed its name to Lineage Cell Therapeutics Inc. to reflect its focus on the research and development of stem cell therapies. Lineage Cell Therapeutics develops and markets cell therapy products based on its own patents and discoveries, including therapies for eye, neurodegenerative, and cancer diseases. The company's proprietary technology platform gives it a crucial position in the field of cell therapy. Additionally, Lineage Cell Therapeutics collaborates with academic institutions and other biopharmaceutical companies to expedite the process of commercializing cell therapies. The company offers a wide range of cell therapies for various injuries and diseases, with key applications including: - OPC1: A cell-based therapy for spinal cord injuries caused by damage to the spinal cord. This therapy is being developed on the astrocyte differentiation treatment platform derived from embryonic stem cells (ES cells). - OpRegen: A cell-based regenerative product for dry age-related macular degeneration (tAMD). This therapy is based on the retinal pigment epithelium cell differentiation treatment platform derived from human embryonic stem cells. - VAC: An immunotherapy for cancer treatment. This treatment involves dendritic cells isolated from the patient's blood and genetically modified to present cancer-specific antigens. The goal is to stimulate the patient's immune system to trigger a specific immune response against cancer. Lineage Cell Therapeutics also pursues a strong expansion strategy. In 2020, it acquired a majority stake in AgeX Therapeutics, a biotechnology company focused on developing innovations in the field of stem cells. This acquisition strengthened the company's capacity for innovation and increased its ability to capitalize on future growth opportunities through partnerships, licensing, and product launches. Overall, Lineage Cell Therapeutics has become a significant player in the field of cell therapy, thanks to the use of cutting-edge technology and years of experience in the life science industry. One of the company's main goals is to develop and manufacture groundbreaking cell therapies to ultimately improve the lives of patients worldwide. Lineage Cell Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lineage Cell Therapeutics stock

EBIT per Employee of Lineage Cell Therapeutics is -282,844.16 USD in 2025.

EBIT per Employee of Lineage Cell Therapeutics changed from -278,935.06 USD to -282,844.16 USD, representing a 1.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Lineage Cell Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Lineage Cell Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Lineage Cell Therapeutics

All Key Metrics — Lineage Cell Therapeutics